APA

O'Dwyer M. E., Mauro M. J., Blasdel C., Farnsworth M., Kurilik G., Hsieh Y., Mori M. & Druker B. J. (20040226). Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. : Blood.

Chicago

O'Dwyer Michael E, Mauro Michael J, Blasdel Carolyn, Farnsworth Melanie, Kurilik Gwen, Hsieh Yi-Ching, Mori Motomi and Druker Brian J. 20040226. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. : Blood.

Harvard

O'Dwyer M. E., Mauro M. J., Blasdel C., Farnsworth M., Kurilik G., Hsieh Y., Mori M. and Druker B. J. (20040226). Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. : Blood.

MLA

O'Dwyer Michael E, Mauro Michael J, Blasdel Carolyn, Farnsworth Melanie, Kurilik Gwen, Hsieh Yi-Ching, Mori Motomi and Druker Brian J. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. : Blood. 20040226.